Bladder Cancer, Version 5.2017, NCCN Clinical Practice …
https://jnccn.org/downloadpdf/view/journals/jnccn/15/10/article-p1240.pdf
Abstract. This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab.
DA: 85 PA: 66 MOZ Rank: 6 Up or Down: Up